{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:33:22Z","timestamp":1772156002506,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>\n                    Trimethoprim-sulfamethoxazole (TMP\/SMX) is used as prophylaxis against\n                    <jats:italic toggle=\"yes\">Pneumocystis jiroveci<\/jats:italic>\n                    during chemotherapy. Many groups recommend withholding TMP\/SMX during high-dose methotrexate (HDMTX) for concerns that it will delay methotrexate clearance. We compared methotrexate exposure following HDMTX (NCT00549848) in 424 patients including 783 courses that were given concurrently and 602 courses that were not given concurrently with TMP\/SMX. Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL\/min\/m\n                    <jats:sup>2<\/jats:sup>\n                    ,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) \u03bcM,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.23). Among 248 patients (830 courses) on the standard\/high-risk arm (HDMTX ~5 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/24 h), there was slightly higher clearance (95.5 [1.4%] vs. 91.2 [0.8%] mL\/min\/m\n                    <jats:sup>2<\/jats:sup>\n                    ,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.005) in those receiving TMP\/SMX, with no difference in the 42 hour methotrexate concentration (0.59 [4.1%] vs. 0.66 [4.2%] \u03bcM,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.06). There was no difference in neutrophil counts based on TMP\/SMX during HDMTX (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.83). TMP\/SMX also did not have a significant impact on myelosuppression of low-dose methotrexate (40 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) given during continuation therapy among 230 patients enrolled on a prior study (NCT00137111). Thus, we found no evidence for an interaction between methotrexate and TMP\/SMX given prophylactically.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000000606","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T03:45:59Z","timestamp":1466221559000},"page":"449-452","source":"Crossref","is-referenced-by-count":23,"title":["Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate"],"prefix":"10.1097","volume":"38","author":[{"given":"Courtney S.","family":"Watts","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph N.","family":"Sciasci","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Pauley","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Panetta","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deqing","family":"Pei","sequence":"additional","affiliation":[{"name":"Biostatistics, St Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Biostatistics, St Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline M.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Skejby Hospital, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben S.","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Skejby Hospital, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","article-title":"Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments","volume":"72","author":"Pauley","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM198710153171608","article-title":"Pneumocystis carinii pneumonitis","volume":"317","author":"Hughes","year":"1987","journal-title":"N Engl J Med"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 12","key":"R10-20230918","first-page":"15","article-title":"Drug interactions with methotrexate","volume":"12","author":"Evans","year":"1985","journal-title":"J Rheumatol Suppl"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-3476(05)83351-7","article-title":"Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia","volume":"117","author":"Ferrazzini","year":"1990","journal-title":"J Pediatr"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N Engl J Med"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0022-3476(84)80439-4","article-title":"Myelosuppression associated with co-trimoxazole as a prophylactic antibiotic in the maintenance phase of childhood acute lymphocytic leukemia","volume":"105","author":"Woods","year":"1984","journal-title":"J Pediatr"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0609.2011.01695.x","article-title":"Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate\/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia","volume":"88","author":"Levinsen","year":"2012","journal-title":"Eur J Haematol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity","volume":"12","author":"Relling","year":"1994","journal-title":"J Clin Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.hoc.2009.07.009","article-title":"Risk-adapted treatment of pediatric acute lymphoblastic leukemia","volume":"23","author":"Jeha","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/pbc.24921","article-title":"Nordic Society of Paediatric Haematology, Oncology. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer","volume":"61","author":"Levinsen","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"VanWert","year":"2008","journal-title":"Pharm Res"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","article-title":"The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP","volume":"13","author":"Van Aubel","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpt1969106849","article-title":"The effect of organic acids on renal clearance of methotrexate in man","volume":"10","author":"Liegler","year":"1969","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00043426-198100320-00001","article-title":"Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia","volume":"3","author":"Beach","year":"1981","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.090153","article-title":"Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review","volume":"37","author":"Bourre-Tessier","year":"2010","journal-title":"J Rheumatol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201608000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:01:12Z","timestamp":1694995272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201608000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000606","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727455054.793530152","asserted-by":"object"}]},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}